Cargando…
High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity
T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion. Tim-3 has also been identified in various solid tumors. However, the role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) is not well understood....
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731937/ https://www.ncbi.nlm.nih.gov/pubmed/29254227 http://dx.doi.org/10.18632/oncotarget.22141 |
_version_ | 1783286594804908032 |
---|---|
author | Xu, Liangjing Xu, Jinge Ma, Shoubao Li, Xiaoli Zhu, Mingqing Chen, Suning Han, Yue Tang, Xiaowen Fu, Zhengzheng Qiu, Huiying Yu, Jianhua Wu, Depei Wu, Xiaojin |
author_facet | Xu, Liangjing Xu, Jinge Ma, Shoubao Li, Xiaoli Zhu, Mingqing Chen, Suning Han, Yue Tang, Xiaowen Fu, Zhengzheng Qiu, Huiying Yu, Jianhua Wu, Depei Wu, Xiaojin |
author_sort | Xu, Liangjing |
collection | PubMed |
description | T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion. Tim-3 has also been identified in various solid tumors. However, the role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) is not well understood. In this study, we aimed to explore the role of Tim-3 in patients with de novo AML, and the correlation between Tim-3 and clinicopathological prognosis. The study cohort consisted of 76 patients with de novo non-M3 AML. These patients’ bone marrow samples were collected and then bone marrow mononuclear cells (BMCs) were isolated for flow cytometry to detect Tim-3 expression on blasts. According to FAB type, 76 diagnosed AML patients included in this study were: M0 (n=2), M1 (n=16), M2 (n=20), M4 (n=20), M5 (n=16), and M6 (n=2). A positive expression (>20%) of Tim-3 was found in 87% (66/76) of patients with AML. The average percentage of Tim-3(+) blasts in these AML patients was 58.26 ± 29.23%. Moreover, the frequency of Tim-3 high expression was higher in M4 patients than that in other AML patients according to FAB type (P=0.004). Tim-3 high expression was also closely associated with inv(16) (P=0.01) and C/EBPA mutation (P=0.03). The mutations of the following six genes, i.e., FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, were independent of the Tim-3 expression. Additionally, it is more likely to find higher levels of Tim-3 in the low-risk group than in the intermediate- and high-risk groups (P=0.02). The expression of Tim-3 was positively correlated with CD13 (r=0.36, P=0.001), CD34 (r=0.41, P=0.000), and CD7 (r=0.27, P=0.02) in AML patients. AML patients with high Tim-3 expression achieved significantly high complete remission (CR) rate (P=0.01), while their Tim-3 expression significantly decreased after CR (P=0.01). Blockade of Tim-3 expression on AML blasts significantly reduced the Idarubicin (IDA)-mediated suppression of cell growth and reduction of cell apoptosis in vitro. Collectively, our study suggests that high Tim-3 expression on AML blasts could enhances chemotherapy sensitivity. |
format | Online Article Text |
id | pubmed-5731937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57319372017-12-17 High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity Xu, Liangjing Xu, Jinge Ma, Shoubao Li, Xiaoli Zhu, Mingqing Chen, Suning Han, Yue Tang, Xiaowen Fu, Zhengzheng Qiu, Huiying Yu, Jianhua Wu, Depei Wu, Xiaojin Oncotarget Research Paper T-cell immunoglobulin and mucin domain-containing molecule3 (Tim-3) represents a novel mechanism of T-cell dysfunction and exhaustion. Tim-3 has also been identified in various solid tumors. However, the role of Tim-3 expression on blast cells in acute myeloid leukemia (AML) is not well understood. In this study, we aimed to explore the role of Tim-3 in patients with de novo AML, and the correlation between Tim-3 and clinicopathological prognosis. The study cohort consisted of 76 patients with de novo non-M3 AML. These patients’ bone marrow samples were collected and then bone marrow mononuclear cells (BMCs) were isolated for flow cytometry to detect Tim-3 expression on blasts. According to FAB type, 76 diagnosed AML patients included in this study were: M0 (n=2), M1 (n=16), M2 (n=20), M4 (n=20), M5 (n=16), and M6 (n=2). A positive expression (>20%) of Tim-3 was found in 87% (66/76) of patients with AML. The average percentage of Tim-3(+) blasts in these AML patients was 58.26 ± 29.23%. Moreover, the frequency of Tim-3 high expression was higher in M4 patients than that in other AML patients according to FAB type (P=0.004). Tim-3 high expression was also closely associated with inv(16) (P=0.01) and C/EBPA mutation (P=0.03). The mutations of the following six genes, i.e., FLT3-ITD, NPM1, C-KIT, IDH1/IDH2, DNMT3A, were independent of the Tim-3 expression. Additionally, it is more likely to find higher levels of Tim-3 in the low-risk group than in the intermediate- and high-risk groups (P=0.02). The expression of Tim-3 was positively correlated with CD13 (r=0.36, P=0.001), CD34 (r=0.41, P=0.000), and CD7 (r=0.27, P=0.02) in AML patients. AML patients with high Tim-3 expression achieved significantly high complete remission (CR) rate (P=0.01), while their Tim-3 expression significantly decreased after CR (P=0.01). Blockade of Tim-3 expression on AML blasts significantly reduced the Idarubicin (IDA)-mediated suppression of cell growth and reduction of cell apoptosis in vitro. Collectively, our study suggests that high Tim-3 expression on AML blasts could enhances chemotherapy sensitivity. Impact Journals LLC 2017-10-27 /pmc/articles/PMC5731937/ /pubmed/29254227 http://dx.doi.org/10.18632/oncotarget.22141 Text en Copyright: © 2017 Xu et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (http://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Xu, Liangjing Xu, Jinge Ma, Shoubao Li, Xiaoli Zhu, Mingqing Chen, Suning Han, Yue Tang, Xiaowen Fu, Zhengzheng Qiu, Huiying Yu, Jianhua Wu, Depei Wu, Xiaojin High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title | High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title_full | High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title_fullStr | High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title_full_unstemmed | High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title_short | High Tim-3 expression on AML blasts could enhance chemotherapy sensitivity |
title_sort | high tim-3 expression on aml blasts could enhance chemotherapy sensitivity |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731937/ https://www.ncbi.nlm.nih.gov/pubmed/29254227 http://dx.doi.org/10.18632/oncotarget.22141 |
work_keys_str_mv | AT xuliangjing hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT xujinge hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT mashoubao hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT lixiaoli hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT zhumingqing hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT chensuning hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT hanyue hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT tangxiaowen hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT fuzhengzheng hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT qiuhuiying hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT yujianhua hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT wudepei hightim3expressiononamlblastscouldenhancechemotherapysensitivity AT wuxiaojin hightim3expressiononamlblastscouldenhancechemotherapysensitivity |